AbbVie (ABBV) – Investment Analysts’ Weekly Ratings Updates

A number of research firms have changed their ratings and price targets for AbbVie (NYSE: ABBV):

• 7/15/2026 – AbbVie had its price target raised by Citigroup Inc. from $230.00 to $260.00. They now have a “neutral” rating on the stock.
• 7/13/2026 – AbbVie had its price target raised by UBS Group AG from $230.00 to $260.00. They now have a “neutral” rating on the stock.
• 7/13/2026 – AbbVie had its price target raised by BMO Capital Markets from $258.00 to $300.00. They now have an “outperform” rating on the stock.
• 7/10/2026 – AbbVie had its price target raised by Wells Fargo & Company from $260.00 to $295.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – AbbVie had its price target raised by Bank of America Corporation from $234.00 to $276.00. They now have a “buy” rating on the stock.
• 7/10/2026 – AbbVie had its price target raised by Royal Bank Of Canada from $260.00 to $280.00. They now have an “outperform” rating on the stock.
• 7/9/2026 – AbbVie had its price target raised by Guggenheim from $249.00 to $261.00. They now have a “buy” rating on the stock.
• 7/9/2026 – AbbVie had its price target raised by JPMorgan Chase & Co. from $260.00 to $280.00. They now have an “overweight” rating on the stock.
• 7/6/2026 – AbbVie had its “buy” rating reaffirmed by HSBC Holdings plc. They now have a $300.00 price target on the stock.
• 7/6/2026 – AbbVie had its price target raised by Cantor Fitzgerald from $240.00 to $265.00. They now have an “overweight” rating on the stock.
• 7/5/2026 – AbbVie was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/27/2026 – AbbVie was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 6/23/2026 – AbbVie had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 6/23/2026 – AbbVie had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/23/2026 – AbbVie had its price target raised by Canaccord Genuity Group Inc. from $265.00 to $273.00. They now have a “buy” rating on the stock.
• 6/23/2026 – AbbVie had its “overweight” rating reaffirmed by Piper Sandler. They now have a $298.00 price target on the stock.
• 6/22/2026 – AbbVie was given a new $260.00 price target by Wells Fargo & Company.
• 6/8/2026 – AbbVie had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 6/7/2026 – AbbVie was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 5/30/2026 – AbbVie was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/17/2026 – AbbVie was downgraded by Wall Street Zen from “strong-buy” to “buy”.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.7%. AbbVie’s dividend payout ratio is presently 340.89%.

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.